(CATX) Perspective Therapeutics - Overview
Stock: Alpha-Emitters, Radiopharmaceuticals, Neuroendocrine, Melanoma, Prostate
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 115% |
| Relative Tail Risk | -13.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | 11.85 |
| Character TTM | |
|---|---|
| Beta | 1.481 |
| Beta Downside | 1.017 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.71% |
| CAGR/Max DD | 0.06 |
Description: CATX Perspective Therapeutics December 30, 2025
Perspective Therapeutics (NASDAQ CATX) develops precision-targeted alpha-particle radiopharmaceuticals for oncology, focusing on tumors that express specific surface receptors. Its lead candidate, VMT-a-NET, is in a Phase 1/2a trial for unresectable or metastatic somatostatin-receptor-2 (SSTR2) positive neuroendocrine tumors that have not received prior peptide-targeted beta therapy such as Lutathera.
Additional pipelines include VMT01 (Phase 1/2a for MC1R-positive metastatic melanoma), PSV359 (fibroblast-activation-protein-alpha-targeted alpha therapy), and PSV4XX (PSMA-targeted alpha therapy for prostate cancer). The company has a clinical-trial collaboration with Bristol Myers Squibb to test [¹²²Pb] VMT01 combined with nivolumab in MC1R-positive melanoma patients.
From a financial-metric standpoint, Perspective reported cash and cash equivalents of roughly $32 million at the end of Q2 2024, giving it an estimated 12-month runway at its current burn rate of $2.5 million per month. The radiopharmaceutical sector is expanding at a compound annual growth rate of ~10 % through 2030, driven by increasing FDA approvals of targeted radionuclide therapies and rising reimbursement comfort.
Key economic drivers for the company include the scarcity of alpha-emitting isotopes (e.g., ²¹²Pb) and the need for scalable production, as well as the broader shift toward precision oncology that favors agents with high tumor-to-normal-tissue dose differentials.
For a deeper quantitative view, you might explore Perspective Therapeutics’ profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -105.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -25.03 > 1.0 |
| NWC/Revenue: 18.8k% < 20% (prev 71.8k%; Δ -53.0k% < -1%) |
| CFO/TA -0.29 > 3% & CFO -84.4m > Net Income -105.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.3m) vs 12m ago 5.19% < -2% |
| Gross Margin: -166.3% > 18% (prev 1.0%; Δ -16.7k% > 0.5%) |
| Asset Turnover: 0.25% > 50% (prev 0.09%; Δ 0.16% > 0%) |
| Interest Coverage Ratio: -281.0 > 6 (EBITDA TTM -105.2m / Interest Expense TTM 385.0k) |
Altman Z'' -7.83
| A: 0.54 (Total Current Assets 178.5m - Total Current Liabilities 20.6m) / Total Assets 294.8m |
| B: -1.01 (Retained Earnings -297.4m / Total Assets 294.8m) |
| C: -0.32 (EBIT TTM -108.2m / Avg Total Assets 343.0m) |
| D: -5.65 (Book Value of Equity -297.2m / Total Liabilities 52.6m) |
| Altman-Z'' Score: -7.83 = D |
Beneish M -2.64
| DSRI: 0.33 (Receivables 179.0k/217.0k, Revenue 841.0k/337.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.90 (AQ_t 0.17 / AQ_t-1 0.19) |
| SGI: 2.50 (Revenue 841.0k / 337.0k) |
| TATA: -0.07 (NI -105.8m - CFO -84.4m) / TA 294.8m) |
| Beneish M-Score: -2.64 (Cap -4..+1) = A |
What is the price of CATX shares?
Over the past week, the price has changed by +24.27%, over one month by +67.62%, over three months by +111.21% and over the past year by +38.12%.
Is CATX a buy, sell or hold?
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CATX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.9 | 172.8% |
| Analysts Target Price | 12.9 | 172.8% |
| ValueRay Target Price | 5.4 | 13.6% |
CATX Fundamental Data Overview February 05, 2026
P/B = 2.4456
Revenue TTM = 841.0k USD
EBIT TTM = -108.2m USD
EBITDA TTM = -105.2m USD
Long Term Debt = 1.58m USD (from longTermDebt, last quarter)
Short Term Debt = 759.0k USD (from shortTermDebt, last quarter)
Debt = 3.31m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.4m USD (from netDebt column, last quarter)
Enterprise Value = 215.7m USD (386.6m + Debt 3.31m - CCE 174.1m)
Interest Coverage Ratio = -281.0 (Ebit TTM -108.2m / Interest Expense TTM 385.0k)
EV/FCF = -2.07x (Enterprise Value 215.7m / FCF TTM -104.4m)
FCF Yield = -48.39% (FCF TTM -104.4m / Enterprise Value 215.7m)
FCF Margin = -12.4k% (FCF TTM -104.4m / Revenue TTM 841.0k)
Net Margin = -12.6k% (Net Income TTM -105.8m / Revenue TTM 841.0k)
Gross Margin = -166.3% ((Revenue TTM 841.0k - Cost of Revenue TTM 2.24m) / Revenue TTM)
Gross Margin QoQ = none% (prev -152.8%)
Tobins Q-Ratio = 0.73 (Enterprise Value 215.7m / Total Assets 294.8m)
Interest Expense / Debt = 1.96% (Interest Expense 65.0k / Debt 3.31m)
Taxrate = 21.0% (US default 21%)
NOPAT = -85.5m (EBIT -108.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.66 (Total Current Assets 178.5m / Total Current Liabilities 20.6m)
Debt / Equity = 0.01 (Debt 3.31m / totalStockholderEquity, last quarter 242.2m)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -23.4m / EBITDA -105.2m)
Debt / FCF = 0.22 (negative FCF - burning cash) (Net Debt -23.4m / FCF TTM -104.4m)
Total Stockholder Equity = 270.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.85% (Net Income -105.8m / Total Assets 294.8m)
RoE = -39.07% (Net Income TTM -105.8m / Total Stockholder Equity 270.8m)
RoCE = -39.71% (EBIT -108.2m / Capital Employed (Equity 270.8m + L.T.Debt 1.58m))
RoIC = -31.36% (negative operating profit) (NOPAT -85.5m / Invested Capital 272.5m)
WACC = 11.29% (E(386.6m)/V(389.9m) * Re(11.37%) + D(3.31m)/V(389.9m) * Rd(1.96%) * (1-Tc(0.21)))
Discount Rate = 11.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.33%
Fair Price DCF = unknown (Cash Flow -104.4m)
EPS Correlation: -61.86 | EPS CAGR: 0.47% | SUE: 3.03 | # QB: 1
Revenue Correlation: -88.21 | Revenue CAGR: -49.51% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.36 | Chg30d=-0.006 | Revisions Net=-2 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.35 | Chg30d=+0.006 | Revisions Net=-1 | Growth EPS=-11.2% | Growth Revenue=-15.2%